个人简介

齐晓伟，男，陆军军医大学西南医院乳腺甲状腺外科副主任、副书记，医学博士，副主任医师、副教授，博士研究生导师。获重庆市杰出青年、重庆市中青年医学高端人才、陆军军医大学红医名师、西南杰青英才等称号。长期从事乳腺癌微创外科的临床研究以及乳腺癌精准治疗的基础与转化研究，以第一或通讯作者在JAMA Surg，Adv Mater，Br J Cancer，BBA-Rev Cancer，J Nanobiotechnology，Breast Cancer Res，Oncologist等杂志发表SCI论文20余篇，其中影响因子≥10分或JCR 1区论文共8篇。主持国家自然科学基金、国家重点研发计划子课题、重庆市杰出青年基金、重庆市技术创新与应用发展重点项目等课题20余项。以第一发明人获国家发明专利9项，副主编/参编乳腺专著10部，执笔/参编行业共识指南9部。获重庆市科技进步一等奖1项（排第3），陆军军医大学临床新技术新业务一级乙等及二级甲等各1项（均排第1）、中华科技进步一等奖一等奖1项（排第15）。兼任中国临床肿瘤学会乳腺癌专业委员会委员、中国临床肿瘤学会青年专家委员会委员、中国抗癌协会转移专业委员会委员、中国抗癌协会中西医整合甲状腺癌专业委员会委员、中华医学会肿瘤学分会乳腺肿瘤学组青年委员、重庆市医学会乳腺病分会常委、重庆市医学会肿瘤学分会乳腺癌学组副组长、重庆市抗癌协会乳腺癌专业委员会常委以及《中华乳腺病杂志》、《中华普外科手术学杂志》、《中国普通外科杂志》编委等。

研究领域

1.乳腺癌微创外科与精准综合治疗的临床及转化研究

2.微环境与乳腺癌复发转移机制关系的基础与转化研究

3.小分子化合物的研发及其在乳腺癌治疗中的应用研究

承担的主要项目

[1]外泌体LINC01241通过WT1-PFKFB4通路诱导三阴性乳腺癌发生糖代谢重编程及化疗抵抗的研究，国家自然科学基金面上项目,2024/01-2027/12,49万，主持

[2]派安普利单抗联合白蛋白紫杉醇和卡铂新辅助治疗三阴性乳腺癌有效性和安全性的前瞻性、单臂、多中心临床研究，国家卫生健康委创新药物上市后临床研究科研专项，2023/07-2025/06,20万，主持

[3]难治性乳腺癌耐药机制研究，重庆市杰出青年自然科学基金，2023/07- 2026/06，100万元，主持

[4]基于临床指导的新型肿瘤药敏分析技术研究及原型产品研制，第一级课题：肿瘤细胞体外药敏技术体系的临床评估及验证，国家重点研发计划子课题，2022/11- 2025/10，24万，主持。

[5]特定环境条件下干细胞对组织器官发育和功能重塑的调控，第一级课题：特定环境条件下组织器官功能重塑的评价和干细胞干预策略，国家重点研发计划子课题，2014.1-2017.12，20万，主持。

[6]基于肿瘤类器官模型构建难治性乳腺癌精准靶向救治体系，重庆市技术创新与应用发展重点项目，2023/01- 2025/12，100万，主持

[7]重庆市中青年医学高端人才项目，重庆市委组织部、重庆市卫生健康委员会，2022/1-2024/12，30万元，主持

[8]曲妥珠联合吡咯替尼或帕妥珠新辅助治疗HER2阳性乳腺癌的真实世界研究，重庆市卫生健康委员会，2022/1-2024/12，16万元，主持

[9]曲妥珠单抗联合吡咯替尼或曲妥珠单抗联合帕妥珠单抗新辅助治疗HER2阳性早期或局部晚期乳腺癌获益人群的影像组学研究(2022年度)，希思科一朝阳肿瘤研究基金项目，10万元，参与

[10]曲妥珠单抗联合呲咯替尼或曲妥珠单抗联合帕妥珠单抗新辅助治疗HER2阳性早期或局部晚期乳腺癌优势获益人群精准筛选的真实世界研究(2022年度)，上海市防癌抗癌事业发展基金会-恒瑞科研项目，6万元，参与

[11]莲心碱衍生物8d抑制三阴性乳腺癌增殖的作用和机制研究，重庆市教委科学技术研究面上项目，2022/10-2024/10，8万，主持

[12]陆军军医大学第一附属医院“DZ型”医院建设项目，陆军军医大学第一附属医院，2022/11-2023/10，50万，主持

[13]曲妥珠单抗联合吡咯替尼新辅助治疗HER2阳性乳腺癌的疗效标志物探索研究，吴阶平医学基金会临床科研专项资助基金(2021年度)，6万元，参与

代表性成果

[1]Andi Wan, Guozhi Zhang, Dandan Ma, Yi Zhang*, Xiaowei Qi*（共同通讯）. An overview of the research progress of BRCA gene mutations in breast cancer. BBA-Rev Cancer, 2023, 1878(4):188907(IF:11.414, JCR:1区)

[2]Qiyun Shi#, Juncheng Xuhong#, Tao Luo#, Jia Ge, Feng Liu, Yang Lan, Qingqiu Chen, Peng Tang, Linjun Fan, Li Chen, Yan Liang, Minghao Wang, Ying Hu, Yi Zhang, Xiuwu Bian*, Xiaowei Qi*（共同通讯）, Jun Jiang*. PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer. Br J Cancer, 2023, 128(1):121-129. (IF:9.075, JCR:1区)

[3]Qiyun Shi, Juncheng Xuhong, Hao Tian, Man Qu, Yi Zhang, Jun Jiang*, Xiaowei Qi*（共同通讯）. Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: A systematic review and meta-analysis. BBA-Rev Cancer, 2023, 1878(1):188847(IF:11.414, JCR:1区)

[4]Tingting Zhao#, Pingping Gao#, Yanling Li#, Hao Tian , Dandan Ma, Na Sun, Ceshi Chen*, Yi Zhang*, Xiaowei Qi*（共同通讯）. Investigating the role of FADS family members in breast cancer based on bioinformatic analysis and experimental validation. Front Immunol, 2023:14:1074242. (IF:8.786, JCR:2区)

[5]Hao Tian#, Man Qu#, Guozhi Zhang, Long Yuan, Qiyun Shi, Yinhuan Wang, Ying Yang, Yi Zhang*, Xiaowei Qi*（共同通讯）. Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations. Oncologist, 2023, 28(7):e534-e541. (IF:5.84, JCR:2区)

[6]Andi Wan#, Yan Liang#, Li Chen#, Shushu Wang, Qiyun Shi, Wenting Yan, Xiaozhen Cao, Ling Zhong, Linjun Fan, Peng Tang, Guozhi Zhang , Siyi Xiong, Cheng Wang , Zhen Zeng, Xiujuan Wu, Jun Jiang*, Xiaowei Qi*（共同通讯）, Yi Zhang*. Association of Long-term Oncologic Prognosis With Minimal Access Breast Surgery vs Conventional Breast Surgery. JAMA Surg, 2022, 157(12):e224711. (IF:16.681, JCR:1区)

[7]Xilan Li#, Yun Liu*, Xiaowei Qi#(共同第一), Shilin Xiao, Zhongsheng Xu, Zhixian Yuan, Qi Liu, Haisheng Li, Siyuan Ma, Tengfei Liu, Yong Huang, Xiaorong Zhang, Xiao Zhang, Zhengwei Mao*, Gaoxing Luo*, Jun Deng*. Sensitive Activatable Nanoprobes for Real-time Ratiometric Magnetic Resonance Imaging of Reactive Oxygen Species and Ameliorating Inflammation In Vivo. Adv Mater, 2022, 4(19):e2109004. (IF:32.086, JCR:1区)

[8]Peng Yan#,Rong Zeng#, Bo Bao, Xiu-Ming Yang, Lei Zhu, Bin Pan, Sheng-Li Niu, Xiao-Wei Qi*（共同通讯）, Yu-Long Li*, Qin Ouyang*. Red-Light-Induced Highly Efficient Aerobic Oxidation of Organoboron Compounds Using Spinach as Photocatalyst. Green Chem, 2022, 24:9263-9268. (IF:11.034, JCR:1区)

[9]Wenting Yan#, Xiujuan Wu#, Shushu Wang, Cheng He, Ling Zhong, Peng Tang, Lin Ren, Ting Zhang, Xiaowei Qi*(共同通讯), and Yi Zhang*. Lobaplatin-Based Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A 5-Year Follow-up of a Randomized, Open-Label, Phase II Trial. Ther Adv Med Oncol, 2022, 14:17588359221107111. (IF:5.485, JCR:2区)

[10]Hao Tian#, Tingting Zhao#,Yanling Li#, Na Sun, Dandan Ma, Qiyun Shi, Guozhi Zhang, Qingqiu Chen, Kongyong Zhang, Ceshi Chen#, Yi Zhang*, Xiaowei Qi*(共同通讯). Chromobox Family Proteins as Putative Biomarkers for Breast Cancer Management: A Preliminary Study Based on Bioinformatics. Analysis and qRT-PCR Validation. Breast Cancer: Targets and Therapy, 2022,14:515-535. (IF:5.008, JCR:2区)

[11]Yinhuan Wang#, Hao Tian#, Xianchun Chen#, Jiasi Zhang, Li Wang, Haiyan Fan, Yi Zhang1, Xiaowei Qi*（共同通讯）, Shaoyi Hu* and Ying Yang*. Safety and feasibility assessment of extending the flushing interval in totally implantable venous access port flushing during the non-treatment stage for patients with breast cancer. Front Oncol, 2022, 12:1021488.(IF:5.738, JCR:2区)

[12]Hao Tian, Guozhi Zhang, Yan Liang, Jing Liu, Linjun Fan, Kai Zhu, Yi Zhang, Xiaowei Qi*. Phase 2 study of anlotinib combined with taxanes and lobaplatin in the neoadjuvant treatment of triple-negative breast cancer: Efficacy, safety and biomarker analysis. Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) e12605-e12605. (IF:50.717, JCR:1区)

[13] Feiyang Liu, Dandan Ma, Qingsong Liu*, Xiaowei Qi*. A novel patient-derived organoid model for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy for screening personalized drugs.Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) e12625-e12625. (IF:50.717, JCR:1区)

[14]Yuting Jin#, Long Yuan#, Yi Zhang, Peng Tang, Ying Yang, Linjun Fan, Li Chen, Xiaowei Qi*(共同通讯), Jun Jiang*. A Prospective Self-Controlled Study of Indocyanine Green, Radioisotope, and Methylene Blue for Combined Imaging of Axillary Sentinel Lymph Nodes in Breast Cancer. Front Oncol, 2022,12:803804. (IF:5.738, JCR:2区)

[15]Cheng Wang#,, Liyong Zhang#,Lin Ren#,, Guozhi Zhang, Andi Wan, Siyi Xiong, Hao Tian, Zaihui Peng, Tingting Zhao, Pingping Gao, Na Sun*, Yi Zhang*, Xiaowei Qi*(共同通讯). A novel pyroptosis-related indicator of immune infiltration features and prognosis in breast cancer. Front Oncol, 2022,12:961500. (IF:5.738, JCR:2区)

[16]Hao Tian#, Dandan Ma#, Xuanni Tan, Wenting Yan, Xiujuan Wu, Cheng He, Ling Zhong, Yan Zhang, Bingjie Yu, Yi Zhang*, Xiaowei Qi*(共同通讯). Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Systematic Review. Front Pharmacol, 2021,12:770663.(IF:5.988, JCR:1区)

[17]Zaihui Peng, Xiaochun Zhang, Long Yuan, Ting Li, Yajie Chen, Hao Tian, Dandan Ma, Jun Deng*, Xiaowei Qi*(共同通讯), Xuntao Yin*. Integrated endotoxin-adsorption and antibacterial properties of platelet-membrane-coated copper silicate hollow microspheres for wound healing. J Nanobiotechnology, 2021, 19(1):383. (IF:9.429, JCR:1区)

[18]Zaihui Peng#, Long Yuan#, Juncheng XuHong, Hao Tian, Yi Zhang*, Jun Deng*, Xiaowei Qi*(共同通讯). Chiral nanomaterials for tumor therapy: autophagy, apoptosis, and photothermal ablation. J Nanobiotechnology, 2021, 19(1):220. (IF:9.429, JCR:1区)

[19]Qiyun Shi, Juncheng Xuhong, Jia Ge, Feng Liu, Yang Lan, Yi Zhang, Tao Luo, Xiuwu Bian, Xiaowei Qi*(共同通讯), Jun Jiang*. Tumor mutation burden and PIK3CA mutations are associated with pathological complete response in human epidermal growth factor receptor 2-positive breast cancer patients. J Clin Oncol, 2021, 39 (15_suppl): e12610-e12610. (IF:50.717, JCR:1区)

[20]Na Su#, Dandan Ma#, Pingping Gao, Yanling Li, Zexuan Yan, Zaihui Peng, Fei Han, Yi Zhang*, Xiaowei Qi*(共同通讯). Construction of a Prognostic Risk Prediction Model for Obesity Combined With Breast Cancer. Front Endocrinol (Lausanne), 2021,12:712513. (IF:6.055, JCR:2区)

[21]Ping-Ping Gao#, Xiao-Wei Qi#(共同第一), Na Sun, Yuan-Yuan Sun, Ye Zhang, Xuan-Ni Tan, Jun Ding, Fei Han*, Yi Zhang*. The emerging roles of dual-specificity phosphatases and their specific characteristics in human cancer. Biochim Biophys Acta Rev Cancer, 2021, 1876(1):188562. (IF:11.414, JCR:1区)

[22]Na Sun, Pingping Gao, Yanling Li, Zexuan Yan, Zaihui Peng, Yi Zhang, Fei Han*, Xiaowei Qi*(共同通讯). Screening and Identification of Key Common and Specific Genes and Their Prognostic Roles in Different Molecular Subtypes of Breast Cancer. Front Mol Biosci, 2021, 8:619110. (IF:6.113, JCR:2区)

[23] Ju Wang, Yi Zhang, Jun Jiang, Xiaowei Qi*. Risk factors for all-cause death and breast cancer-specific death in patients with HER2-positive and lymph node negative breast cancer: A retrospective analysis based on SEER database (2010 to 2017). Cancer Res, 2021, 81(4 Suppl):Abstract nr PS10-39. (IF:13.312, JCR:1区)

[24]Jun-Cheng Xuhong#, Xiao-Wei Qi#(共同第一), Peng Tang#, Linjun Fan, Li Chen, Fan Zhang, Xuanni Tan, Wenting Yan, Ling Zhong, Cheng He, Yan Liang, Lin Ren, Minghao Wang, Yi Zhang*, Jun Jiang*.Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I–III HER2-Positive Breast Cancer: A Phase II Clinical Trial. Oncologist, 2020, 25(12):e1909-e1920. (IF:5.837, JCR:2区)

[25]Ju Wang, Ye Zhang, Long Yuan, Lin Ren, Yi Zhang, Xiaowei Qi*. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2- negative metastatic or advanced breast cancer: a networkmeta-analysis. Aging (Albany NY), 2020, 13(1):450-459. (IF:5.955, JCR:2区)

[26]Yanling Li#, Hao Tian#, Jun Jiang, Yi Zhang*, Xiao-Wei Qi*(共同通讯). Multifaceted regulation and functions of fatty acid desaturase 2 in human cancers. Am J Cancer Res, 2020,10(12):4098-4111. (IF:5.942, JCR:2区)

[27]Ye Zhang, Lin-Jun Fan, Yi Zhang, Jun Jiang, Xiao-Wei Qi*. Long Non-coding Wilms Tumor 1 Antisense RNA in the Development and Progression of Malignant Tumors. Front Oncol, 2020, 10:35.(IF:5.738, JCR:2区)

[28]Ye Zhang*, Wen-Ting Yan*, Ze-Yu Yang*, Yan-Ling Li, Xuan-Ni Tan, Jun Jiang, Yi Zhang, Xiao-Wei Qi*. The role of WT1 in breast cancer: clinical implications, biological effects and molecular mechanism. Int J Biol Sci, 2020, 16(8): 1474-1480. (IF:10.750, JCR:1区)

[29]Long Yuan#, Xiaowei Qi#(共同第一), Gaoping Qin, Qi Liu, Fan Zhang*, Yong Song*, Jun Deng*. Effects of gold nanostructures on differentiation of mesenchymal stem cells. Colloids Surf B Biointerfaces, 2019, 184:110494. (IF:5.999, JCR:1区)

[30]Jun-Cheng Xuhong#, Xiao-Wei Qi#(共同第一), Yi Zhang*, Jun Jiang*. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. Am J Cancer Res, 2019, 9(10):2103-2119. (IF:5.942, JCR:2区)

[31]Baoquan Hu, Wenting Yan, Minghao Wang, Xiang Cui, Ying Hu, Qingqiu Chen, Yi Zhang, Xiaowei Qi（共同通讯）*, Jun Jiang*. Huaier polysaccharide inhibits the stem-like characteristics of ERα-36high triple negative breast cancer cells via inactivation of the ERα-36 signaling pathway. Int J Biol Sci, 2019; 15(7):1358-1367. (IF:10.750, JCR:2区)

[32]Xiaowei Qi, Long Yuan, Yi Zhang, Jun Jiang*. Comparison of sentinel lymph node detection performances using methylene blue in conjunction with indocyanine green or radioisotope in breast cancer patients: A prospective single-center cohort study. Cancer Res, 2019;79(4 Suppl):Abstract nr P3-03-01. (IF:13.312, JCR:1区)

[33]Yanling Li#, Sijie Gan#, Lin Ren#, Long Yuan, Junlan Liu, Wei Wang, Xiaoyu Wang, Yi Zhang, Jun Jiang, Fan Zhang*, and Xiaowei Qi（共同通讯）*. Multifaceted regulation and functions of replication factor C family in human cancers. Am J Cancer Res, 2018; 8(8): 1343-1355. (IF:5.942, JCR:2区)

[34]Xiaoyu Wang#, Long Yuan#, Yanling Li#, Sijie Gan, Lin Ren, Fan Zhang, Jun Jiang*, Xiaowei Qi（共同通讯）*. RNA activation technique and its applications in cancer research. Am J Cancer Res, 2018, 8(4):584-593. (IF:5.942, JCR:2区)

[35]Long Yuan#, Xiaowei Qi#（共同第一）, Yi Zhang, Xinhua Yang, Fan Zhang, Linjun Fan, Li Chen, Kongyong Zhang, Ling Zhong, Yanling Li, Sijie Gan, Wenying Fu and Jun Jiang*. Comparison of sentinel lymph node detection performances using blue dye in conjunction with indocyanine green or radioisotope in breast cancer patients: a prospective single-center randomized study. Cancer Biol Med, 2018 ,15(4):452-460. (IF:5.347, JCR:2区)

[36]Xiaowei Qi, Xiaodong Zheng, Beige Zong, Qingqiu Chen, Fan Zhang, Xinhua Yang, Yi Zhang, Junlan Liu, Jun Jiang*. Association between WT1 polymorphisms and susceptibility to breast cancer: results from a case-control study in a southwestern Chinese population. Am J Cancer Res, 2015, 5(3) 1234-1250. (IF:5.942, JCR:2区)

[37]Xiaowei Qi, Xinhua Yang, Linjun Fan, Yi Zhang, Fan Zhang, Jun Jiang*. WT1 promotes the proliferation, invasion and migration of breast cancer cells through regulating Id1. Eur J Cancer, 2013, 49(S1):S3-S4. (IF:10.002, JCR:1区)

[38]Xiaowei Qi, Xinhua Yang, Linjun Fan, Yi Zhang, Fan Zhang, Jun Jiang. Association between the spread of circulating tumor cells and breast cancer subtypes. Breast Cancer Res, 2010, 12(3): 402. (IF:8.408, JCR:1区)

[39]《乳腺疾病腔镜手术治疗》，编者，人民卫生出版社，2012.3.1

[40]《乳腺外科手术图谱》，编者，人民军医出版社，2014.7.1

[41]《现代乳腺外科学》，编者，人民卫生出版社，2014.12.1

[42]《乳腺外科临床工作手册》，编者，中华医学音像电子出版社，2017.6.1

[43]《乳腺癌经典文献解读》，编者，北京大学医学出版社，2017.9.1

[44]《中国中青年医生乳腺癌手术视频精选集》，编者，中南大学出版社，2020.10

[45]《乳腺癌》，编者，AME出版社，2020.03

[46]《乳腺恶性疾病病例精解》，副主编，科学技术文献出版社，2021.01

[47]《探秘乳房》，编者，郑州大学出版社，2021.1

[48]《乳腺癌病例集锦2021》，编者，中华医学电子音像出版社，2021.08

[49]《甲状腺癌》，编者，人民卫生出版社，2021.12

[50]《中国临床肿瘤学年度研究进展》，编者，人民卫生出版社，2023.6

[51]2019年复发/转移性乳腺癌标志物临床应用专家共识，参编

[52]2021年大数据驱动下乳腺癌精准诊疗的临床指导，参编

[53]2021年中国家族遗传性肿瘤临床诊疗专家共识—家族遗传性乳腺癌，参编

[54]2022年早期乳腺癌女性患者的骨健康管理中国专家共识，参编

[55]2022年乳腺癌前哨淋巴结活检规范化操作指南，执笔

[56]2022年中国年轻乳腺癌诊疗专家共识，参编

[57]2022年基于靶标指导乳腺癌精准治疗标志物临床应用专家共识，参编

[58]2022中国年轻乳腺癌诊疗专家共识，参编

[59]2022人表皮生长因子受体2低表达乳腺癌临床诊疗共识，参编

[60]2023白蛋白结合型紫杉醇治疗乳腺癌的中国专家共识，参编

[61]2023中国肿瘤整合整治技术指南-液态活检，参编

[62]齐晓伟，中华医学科技奖一等奖，2011

[63]齐晓伟，优秀共青团员，全军，2012

[64]齐晓伟，陆军军医大学第一附属医院嘉奖，2012/2013/2019

[65]齐晓伟，第三军医大学苗圃人才，2017

[66]齐晓伟，中国医师学会全国中青年乳腺癌手术视频大赛季军，2017

[67]齐晓伟，中国临床肿瘤学会“最具潜力青年肿瘤医师”称号, 2019

[68]齐晓伟，重庆市科技进步一等奖，省部级，2020

[69]齐晓伟，陆军军医大学临床新技术二级甲等，2021

[70]齐晓伟，陆军军医大学第一附属医院科研工作先进个人，2021

[71]齐晓伟，中国人民解放军个人三等功，全军，2021

[72]齐晓伟，陆军军医大学红医科研名师，2023

[73]齐晓伟，陆军军医大学临床新技术一级乙等，2023

联系方式

电话：13527545423；E-mail：qxw9908@foxmail.com